Treatments for Plaque Psoriasis

Phase 3 results show risankizumab outperforms secukinumab
January 17, 2020

Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.

Bimekizumab offers hope for skin clearance in psoriasis
December 10, 2019

Newly published results from a phase 3 study demonstrate the superiority of bimekizumab over adalimumab for plaque psoriasis.

Considerations for psoriasis patients with skin of color
November 08, 2019

Psoriasis often has a greater impact on quality of life in patients with skin of color as the condition and its treatment can result in long-lasting pigmentary changes.